| P/E (FY) | 0.6 | Sales (TTM) | $2.9M |
| Earnings (TTM) | -$19.4M | ROE | — |
| Net Margin | 328.67% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 131.12% |
| Market Cap | $7.8M | Trading Days | 578 |
| 52W High | 3.27 |
| 52W Low | 0.46 |
| % Off High | −84.31% |
| YTD | −54.60% | 1Y | −68.33% |
| Since incept. (ann.) | −80.03% |
Single Reportable 100%
| Ann. Volatility (1Y) | 129.86% | Ann. Volatility (3Y) | 150.19% |
| Sharpe (1Y) | −0.23 | Sharpe (3Y) | −0.47 |
| Max Drawdown (1Y) | −84.41% | Max Drawdown (3Y) | −97.72% |
| Beta (3Y, vs SPY) | 0.40 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BOLT | Bolt Biotherapeutics, Inc. | $7.7M | — |
| SYBX | SYNLOGIC, INC. | $7.8M | — |
| APRE | Aprea Therapeutics, Inc. | $7.6M | — |
| CNSP | CNS Pharmaceuticals, Inc. | $7.4M | — |
| MTVA | MetaVia Inc. | $7.4M | — |
| PCSA | Processa Pharmaceuticals, Inc. | $8.4M | — |
| AEON | AEON Biopharma, Inc. | $6.7M | — |
| KAPA | Kairos Pharma, LTD. | $6.6M | — |
| IMNN | Imunon, Inc. | $6.4M | — |
| VTGN | Vistagen Therapeutics, Inc. | $9.6M | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $6.3M |
| — |
| ALZN | Alzamend Neuro, Inc. | $6.3M | — |
